ENSG00000167548 |
|
small cell lung carcinoma |
stop_gained |
11.79% (52/441) |
4 entries |
ENSG00000167548 |
|
cecum adenocarcinoma |
stop_gained |
18.52% (50/270) |
1 entry |
ENSG00000167548 |
|
esophageal squamous cell carcinoma |
missense_variant |
19.49% (138/708) |
8 entries |
ENSG00000167548 |
|
colorectal adenocarcinoma |
frameshift_variant |
10.81% (141/1304) |
4 entries |
ENSG00000167548 |
|
neoplasm of mature B-cells |
missense_variant |
63.92% (62/97) |
4 entries |
ENSG00000167548 |
|
Mantle cell lymphoma |
stop_gained |
20.39% (21/103) |
3 entries |
ENSG00000167548 |
|
bladder transitional cell carcinoma |
missense_variant |
21.17% (116/548) |
4 entries |
ENSG00000167548 |
|
colorectal adenocarcinoma |
missense_variant |
10.81% (141/1304) |
6 entries |
ENSG00000167548 |
|
Mantle cell lymphoma |
missense_variant |
20.39% (21/103) |
3 entries |
ENSG00000167548 |
|
diffuse large B-cell lymphoma |
stop_gained |
27.71% (143/516) |
7 entries |
ENSG00000167548 |
|
esophageal squamous cell carcinoma |
stop_gained |
19.49% (138/708) |
8 entries |
ENSG00000167548 |
|
small cell lung carcinoma |
missense_variant |
11.79% (52/441) |
4 entries |
ENSG00000167548 |
|
Endometrial Endometrioid Adenocarcinoma |
frameshift_variant |
10.31% (67/650) |
2 entries |
ENSG00000167548 |
|
colon adenocarcinoma |
frameshift_variant |
13.38% (173/1293) |
7 entries |
ENSG00000167548 |
|
bladder carcinoma |
missense_variant |
13.37% (75/561) |
2 entries |
ENSG00000167548 |
|
esophageal squamous cell carcinoma |
frameshift_variant |
19.49% (138/708) |
7 entries |
ENSG00000167548 |
|
cecum adenocarcinoma |
sequence_alteration |
18.52% (50/270) |
2 entries |
ENSG00000167548 |
|
small cell lung carcinoma |
frameshift_variant |
11.79% (52/441) |
2 entries |
ENSG00000167548 |
|
neoplasm of mature B-cells |
frameshift_variant |
63.92% (62/97) |
4 entries |
ENSG00000167548 |
|
colon adenocarcinoma |
conservative_inframe_deletion |
13.38% (173/1293) |
4 entries |
ENSG00000167548 |
|
colon adenocarcinoma |
amino_acid_insertion |
13.38% (173/1293) |
1 entry |
ENSG00000167548 |
|
colon adenocarcinoma |
sequence_alteration |
13.38% (173/1293) |
2 entries |
ENSG00000167548 |
|
bladder transitional cell carcinoma |
conservative_inframe_deletion |
21.17% (116/548) |
1 entry |
ENSG00000167548 |
|
esophageal squamous cell carcinoma |
sequence_alteration |
19.49% (138/708) |
3 entries |
ENSG00000167548 |
|
diffuse large B-cell lymphoma |
sequence_alteration |
27.71% (143/516) |
4 entries |
ENSG00000167548 |
|
melanoma |
missense_variant |
20.0% (29/145) |
3 entries |
ENSG00000167548 |
|
melanoma |
conservative_inframe_deletion |
20.0% (29/145) |
1 entry |
ENSG00000167548 |
|
diffuse large B-cell lymphoma |
frameshift_variant |
27.71% (143/516) |
7 entries |
ENSG00000167548 |
|
hemangioblastoma |
sequence_alteration |
50.0% (15/30) |
1 entry |
ENSG00000167548 |
|
diffuse large B-cell lymphoma |
missense_variant |
27.71% (143/516) |
8 entries |
ENSG00000167548 |
|
Mantle cell lymphoma |
frameshift_variant |
20.39% (21/103) |
3 entries |
ENSG00000167548 |
|
bladder transitional cell carcinoma |
stop_gained |
21.17% (116/548) |
4 entries |
ENSG00000167548 |
|
basal cell carcinoma |
sequence_alteration |
35.29% (24/68) |
1 entry |
ENSG00000167548 |
|
colorectal adenocarcinoma |
stop_gained |
10.81% (141/1304) |
2 entries |
ENSG00000167548 |
|
small cell lung carcinoma |
sequence_alteration |
11.79% (52/441) |
2 entries |
ENSG00000167548 |
|
cecum adenocarcinoma |
missense_variant |
18.52% (50/270) |
3 entries |
ENSG00000167548 |
|
Endometrial Endometrioid Adenocarcinoma |
missense_variant |
10.31% (67/650) |
3 entries |
ENSG00000167548 |
|
colon adenocarcinoma |
missense_variant |
13.38% (173/1293) |
8 entries |
ENSG00000167548 |
|
neoplasm of mature B-cells |
stop_gained |
63.92% (62/97) |
5 entries |
ENSG00000167548 |
|
colon adenocarcinoma |
stop_gained |
13.38% (173/1293) |
2 entries |
ENSG00000167548 |
|
colorectal adenocarcinoma |
sequence_alteration |
10.81% (141/1304) |
1 entry |
ENSG00000167548 |
|
cecum adenocarcinoma |
frameshift_variant |
18.52% (50/270) |
4 entries |
ENSG00000167548 |
|
urothelial carcinoma |
stop_gained |
36.05% (31/86) |
1 entry |
ENSG00000167548 |
|
urothelial carcinoma |
frameshift_variant |
36.05% (31/86) |
1 entry |
ENSG00000167548 |
|
bladder carcinoma |
stop_gained |
13.37% (75/561) |
2 entries |
ENSG00000167548 |
|
urothelial carcinoma |
sequence_alteration |
36.05% (31/86) |
1 entry |
ENSG00000167548 |
|
bladder transitional cell carcinoma |
frameshift_variant |
21.17% (116/548) |
6 entries |
ENSG00000167548 |
|
hemangioblastoma |
missense_variant |
50.0% (15/30) |
1 entry |
ENSG00000167548 |
|
basal cell carcinoma |
missense_variant |
35.29% (24/68) |
2 entries |
ENSG00000167548 |
|
bladder transitional cell carcinoma |
sequence_alteration |
21.17% (116/548) |
3 entries |
ENSG00000167548 |
|
bladder carcinoma |
frameshift_variant |
13.37% (75/561) |
1 entry |
ENSG00000167548 |
|
lymphoid neoplasm |
missense_variant |
32.99% (65/197) |
1 entry |
ENSG00000167548 |
|
urothelial carcinoma |
missense_variant |
36.05% (31/86) |
1 entry |
ENSG00000167548 |
|
basal cell carcinoma |
stop_gained |
35.29% (24/68) |
2 entries |
ENSG00000167548 |
|
cecum adenocarcinoma |
conservative_inframe_deletion |
18.52% (50/270) |
1 entry |
ENSG00000167548 |
|
neoplasm of mature B-cells |
sequence_alteration |
63.92% (62/97) |
3 entries |
ENSG00000167548 |
|
esophageal squamous cell carcinoma |
conservative_inframe_deletion |
19.49% (138/708) |
2 entries |
ENSG00000167548 |
|
pancreatic neuroendocrine tumor |
missense_variant |
1.695% (4/236) |
1 entry |
ENSG00000167548 |
|
Mantle cell lymphoma |
translational_product_function_variant |
20.39% (21/103) |
1 entry |
ENSG00000167548 |
|
bile duct adenocarcinoma |
conservative_inframe_deletion |
3.987% (25/627) |
1 entry |
ENSG00000167548 |
|
angiosarcoma |
stop_gained |
7.018% (4/57) |
2 entries |
ENSG00000167548 |
|
Anal Squamous Cell Carcinoma |
stop_gained |
14.46% (12/83) |
2 entries |
ENSG00000167548 |
|
acute lymphoblastic leukemia |
missense_variant |
5.607% (18/321) |
1 entry |
ENSG00000167548 |
|
lung adenocarcinoma |
conservative_inframe_deletion |
5.621% (147/2615) |
2 entries |
ENSG00000167548 |
|
T-cell acute lymphoblastic leukemia |
frameshift_variant |
2.068% (14/677) |
1 entry |
ENSG00000167548 |
|
central nervous system primitive neuroectodermal neoplasm |
missense_variant |
3.934% (19/483) |
3 entries |
ENSG00000167548 |
|
hemangioblastoma |
conservative_inframe_deletion |
50.0% (15/30) |
1 entry |
ENSG00000167548 |
|
esophageal adenocarcinoma |
frameshift_variant |
3.285% (18/548) |
1 entry |
ENSG00000167548 |
|
nasopharyngeal squamous cell carcinoma |
stop_gained |
8.696% (16/184) |
2 entries |
ENSG00000167548 |
|
anaplastic astrocytoma |
stop_gained |
3.053% (4/131) |
1 entry |
ENSG00000167548 |
|
T-cell acute lymphoblastic leukemia |
stop_gained |
2.068% (14/677) |
3 entries |
ENSG00000167548 |
|
squamous cell lung carcinoma |
stop_gained |
8.796% (84/955) |
1 entry |
ENSG00000167548 |
|
B-cell acute lymphoblastic leukemia |
frameshift_variant |
4.487% (7/156) |
2 entries |
ENSG00000167548 |
|
cervical carcinoma |
missense_variant |
8.696% (2/23) |
2 entries |
ENSG00000167548 |
|
skin melanoma |
missense_variant |
8.755% (102/1165) |
6 entries |
ENSG00000167548 |
|
Mixed Lobular and Ductal Breast Carcinoma |
missense_variant |
6.667% (5/75) |
1 entry |
ENSG00000167548 |
|
papillary thyroid carcinoma |
missense_variant |
1.174% (6/511) |
1 entry |
ENSG00000167548 |
|
female breast carcinoma |
missense_variant |
4.11% (12/292) |
2 entries |
ENSG00000167548 |
|
prostate carcinoma |
stop_gained |
5.869% (25/426) |
2 entries |
ENSG00000167548 |
|
breast carcinoma |
stop_gained |
2.75% (47/1709) |
1 entry |
ENSG00000167548 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
stop_gained |
3.788% (10/264) |
2 entries |
ENSG00000167548 |
|
rectal adenocarcinoma |
missense_variant |
4.762% (26/546) |
3 entries |
ENSG00000167548 |
|
B-cell neoplasm |
stop_gained |
11.11% (2/18) |
1 entry |
ENSG00000167548 |
|
major salivary gland adenoid cystic carcinoma |
stop_gained |
8.0% (2/25) |
1 entry |
ENSG00000167548 |
|
lung adenocarcinoma |
sequence_alteration |
5.621% (147/2615) |
2 entries |
ENSG00000167548 |
|
gastric adenocarcinoma |
frameshift_variant |
7.592% (58/764) |
4 entries |
ENSG00000167548 |
|
head and neck squamous cell carcinoma |
frameshift_variant |
4.147% (27/651) |
1 entry |
ENSG00000167548 |
|
adenosquamous lung carcinoma |
missense_variant |
13.64% (3/22) |
2 entries |
ENSG00000167548 |
|
diffuse gastric adenocarcinoma |
stop_gained |
3.571% (4/112) |
2 entries |
ENSG00000167548 |
|
pharyngeal squamous cell carcinoma |
stop_gained |
11.11% (9/81) |
2 entries |
ENSG00000167548 |
|
breast phyllodes tumor |
stop_gained |
11.11% (15/135) |
3 entries |
ENSG00000167548 |
|
brain glioblastoma |
stop_gained |
1.731% (21/1213) |
1 entry |
ENSG00000167548 |
|
breast phyllodes tumor |
frameshift_variant |
11.11% (15/135) |
2 entries |
ENSG00000167548 |
|
Anal Squamous Cell Carcinoma |
missense_variant |
14.46% (12/83) |
1 entry |
ENSG00000167548 |
|
bladder transitional cell carcinoma |
amino_acid_insertion |
21.17% (116/548) |
1 entry |
ENSG00000167548 |
|
myelodysplastic syndrome |
frameshift_variant |
4.179% (29/694) |
1 entry |
ENSG00000167548 |
|
Pancreatic Acinar Cell Carcinoma |
stop_gained |
8.824% (3/34) |
1 entry |
ENSG00000167548 |
|
acute lymphoblastic leukemia |
stop_gained |
5.607% (18/321) |
1 entry |
ENSG00000167548 |
|
melanoma |
frameshift_variant |
20.0% (29/145) |
1 entry |
ENSG00000167548 |
|
prostate carcinoma |
missense_variant |
5.869% (25/426) |
3 entries |
ENSG00000167548 |
|
oral squamous cell carcinoma |
frameshift_variant |
9.924% (26/262) |
4 entries |
ENSG00000167548 |
|
nasopharyngeal squamous cell carcinoma |
frameshift_variant |
8.696% (16/184) |
2 entries |
ENSG00000167548 |
|
marginal zone B-cell lymphoma |
frameshift_variant |
12.9% (4/31) |
2 entries |
ENSG00000167548 |
|
acute lymphoblastic leukemia |
frameshift_variant |
5.607% (18/321) |
2 entries |
ENSG00000167548 |
|
non-small cell lung carcinoma |
missense_variant |
5.155% (5/97) |
2 entries |
ENSG00000167548 |
|
gastric adenocarcinoma |
missense_variant |
7.592% (58/764) |
4 entries |
ENSG00000167548 |
|
marginal zone B-cell lymphoma |
stop_gained |
12.9% (4/31) |
1 entry |
ENSG00000167548 |
|
anaplastic oligodendroglioma |
sequence_alteration |
9.302% (8/86) |
1 entry |
ENSG00000167548 |
|
prostate carcinoma |
frameshift_variant |
5.869% (25/426) |
2 entries |
ENSG00000167548 |
|
chromophobe renal cell carcinoma |
missense_variant |
2.454% (4/163) |
2 entries |
ENSG00000167548 |
|
gastric intestinal type adenocarcinoma |
missense_variant |
12.04% (13/108) |
2 entries |
ENSG00000167548 |
|
testicular seminoma |
missense_variant |
5.128% (4/78) |
1 entry |
ENSG00000167548 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
missense_variant |
3.788% (10/264) |
2 entries |
ENSG00000167548 |
|
acute myeloid leukemia |
missense_variant |
1.063% (28/2633) |
4 entries |
ENSG00000167548 |
|
rectal adenocarcinoma |
frameshift_variant |
4.762% (26/546) |
2 entries |
ENSG00000167548 |
|
breast phyllodes tumor |
missense_variant |
11.11% (15/135) |
2 entries |
ENSG00000167548 |
|
metaplastic breast carcinoma |
frameshift_variant |
9.756% (8/82) |
2 entries |
ENSG00000167548 |
|
Pleural Epithelioid Mesothelioma |
missense_variant |
2.439% (5/205) |
3 entries |
ENSG00000167548 |
|
chronic lymphocytic leukemia |
stop_gained |
0.9858% (9/913) |
2 entries |
ENSG00000167548 |
|
lung carcinoid tumor |
stop_gained |
7.407% (2/27) |
2 entries |
ENSG00000167548 |
|
Breast Carcinoma by Gene Expression Profile |
conservative_inframe_deletion |
7.955% (105/1320) |
1 entry |
ENSG00000167548 |
|
Fibroadenoma |
frameshift_variant |
6.757% (5/74) |
2 entries |
ENSG00000167548 |
|
endometrium adenocarcinoma |
missense_variant |
6.667% (2/30) |
1 entry |
ENSG00000167548 |
|
T-cell acute lymphoblastic leukemia |
missense_variant |
2.068% (14/677) |
3 entries |
ENSG00000167548 |
|
breast ductal adenocarcinoma |
stop_gained |
3.14% (54/1720) |
6 entries |
ENSG00000167548 |
|
brain glioblastoma |
missense_variant |
1.731% (21/1213) |
1 entry |
ENSG00000167548 |
|
adrenal cortex carcinoma |
missense_variant |
1.587% (3/189) |
1 entry |
ENSG00000167548 |
|
Ampulla of Vater Carcinoma |
missense_variant |
4.706% (4/85) |
1 entry |
ENSG00000167548 |
|
myelodysplastic syndrome |
stop_gained |
4.179% (29/694) |
1 entry |
ENSG00000167548 |
|
nasopharyngeal squamous cell carcinoma |
missense_variant |
8.696% (16/184) |
3 entries |
ENSG00000167548 |
|
desmoplastic medulloblastoma |
frameshift_variant |
14.71% (5/34) |
2 entries |
ENSG00000167548 |
|
prostate adenocarcinoma |
frameshift_variant |
3.935% (85/2160) |
5 entries |
ENSG00000167548 |
|
Merkel cell skin cancer |
missense_variant |
15.79% (15/95) |
3 entries |
ENSG00000167548 |
|
prostate adenocarcinoma |
stop_gained |
3.935% (85/2160) |
2 entries |
ENSG00000167548 |
|
bile duct adenocarcinoma |
missense_variant |
3.987% (25/627) |
2 entries |
ENSG00000167548 |
|
Non-Functioning Adrenal Cortex Adenoma |
missense_variant |
9.091% (2/22) |
1 entry |
ENSG00000167548 |
|
neoplasm |
missense_variant |
6.897% (2/29) |
1 entry |
ENSG00000167548 |
|
anaplastic astrocytoma |
missense_variant |
3.053% (4/131) |
1 entry |
ENSG00000167548 |
|
Uterine Carcinosarcoma |
missense_variant |
1.351% (2/148) |
1 entry |
ENSG00000167548 |
|
esophageal adenocarcinoma |
sequence_alteration |
3.285% (18/548) |
1 entry |
ENSG00000167548 |
|
embryonal rhabdomyosarcoma |
missense_variant |
3.488% (3/86) |
2 entries |
ENSG00000167548 |
|
lung adenocarcinoma |
frameshift_variant |
5.621% (147/2615) |
2 entries |
ENSG00000167548 |
|
breast ductal adenocarcinoma |
frameshift_variant |
3.14% (54/1720) |
2 entries |
ENSG00000167548 |
|
oral squamous cell carcinoma |
missense_variant |
9.924% (26/262) |
6 entries |
ENSG00000167548 |
|
Breast Carcinoma by Gene Expression Profile |
missense_variant |
7.955% (105/1320) |
5 entries |
ENSG00000167548 |
|
Invasive Breast Carcinoma |
stop_gained |
6.522% (3/46) |
1 entry |
ENSG00000167548 |
|
Cutaneous Follicular Lymphoma |
frameshift_variant |
100.0% (2/2) |
2 entries |
ENSG00000167548 |
|
laryngeal squamous cell carcinoma |
stop_gained |
17.07% (7/41) |
2 entries |
ENSG00000167548 |
|
oral squamous cell carcinoma |
sequence_alteration |
9.924% (26/262) |
2 entries |
ENSG00000167548 |
|
prostate carcinoma |
sequence_alteration |
5.869% (25/426) |
1 entry |
ENSG00000167548 |
|
oral squamous cell carcinoma |
stop_gained |
9.924% (26/262) |
5 entries |
ENSG00000167548 |
|
urothelial carcinoma |
conservative_inframe_deletion |
36.05% (31/86) |
1 entry |
ENSG00000167548 |
|
prostate adenocarcinoma |
conservative_inframe_deletion |
3.935% (85/2160) |
2 entries |
ENSG00000167548 |
|
lobular breast carcinoma |
frameshift_variant |
3.261% (9/276) |
1 entry |
ENSG00000167548 |
|
Splenic Diffuse Large B-Cell Lymphoma |
frameshift_variant |
75.0% (3/4) |
2 entries |
ENSG00000167548 |
|
gastric intestinal type adenocarcinoma |
frameshift_variant |
12.04% (13/108) |
2 entries |
ENSG00000167548 |
|
metaplastic breast carcinoma |
stop_gained |
9.756% (8/82) |
2 entries |
ENSG00000167548 |
|
small cell lung carcinoma |
conservative_inframe_deletion |
11.79% (52/441) |
1 entry |
ENSG00000167548 |
|
breast ductal adenocarcinoma |
missense_variant |
3.14% (54/1720) |
4 entries |
ENSG00000167548 |
|
undifferentiated pleomorphic sarcoma |
missense_variant |
4.839% (3/62) |
1 entry |
ENSG00000167548 |
|
squamous cell lung carcinoma |
sequence_alteration |
8.796% (84/955) |
1 entry |
ENSG00000167548 |
|
acute myeloid leukemia |
frameshift_variant |
1.063% (28/2633) |
1 entry |
ENSG00000167548 |
|
hepatocellular carcinoma |
missense_variant |
2.632% (26/988) |
2 entries |
ENSG00000167548 |
|
prostate adenocarcinoma |
sequence_alteration |
3.935% (85/2160) |
1 entry |
ENSG00000167548 |
|
carcinosarcoma |
missense_variant |
100.0% (3/3) |
1 entry |
ENSG00000167548 |
|
central nervous system primitive neuroectodermal neoplasm |
stop_gained |
3.934% (19/483) |
2 entries |
ENSG00000167548 |
|
central nervous system primitive neuroectodermal neoplasm |
frameshift_variant |
3.934% (19/483) |
4 entries |
ENSG00000167548 |
|
ovarian serous adenocarcinoma |
missense_variant |
1.779% (15/843) |
3 entries |
ENSG00000167548 |
|
head and neck squamous cell carcinoma |
sequence_alteration |
4.147% (27/651) |
1 entry |
ENSG00000167548 |
|
papillary thyroid carcinoma |
frameshift_variant |
1.174% (6/511) |
1 entry |
ENSG00000167548 |
|
skin melanoma |
stop_gained |
8.755% (102/1165) |
4 entries |
ENSG00000167548 |
|
Gastrointestinal stromal tumor |
missense_variant |
3.289% (5/152) |
1 entry |
ENSG00000167548 |
|
Merkel cell skin cancer |
stop_gained |
15.79% (15/95) |
2 entries |
ENSG00000167548 |
|
myelodysplastic syndrome |
missense_variant |
4.179% (29/694) |
1 entry |
ENSG00000167548 |
|
bile duct adenocarcinoma |
frameshift_variant |
3.987% (25/627) |
1 entry |
ENSG00000167548 |
|
pancreatic ductal adenocarcinoma |
stop_gained |
3.432% (59/1719) |
2 entries |
ENSG00000167548 |
|
lung adenocarcinoma |
stop_gained |
5.621% (147/2615) |
5 entries |
ENSG00000167548 |
|
bile duct adenocarcinoma |
stop_gained |
3.987% (25/627) |
2 entries |
ENSG00000167548 |
|
Gallbladder Adenocarcinoma |
sequence_alteration |
4.651% (8/172) |
1 entry |
ENSG00000167548 |
|
squamous cell lung carcinoma |
frameshift_variant |
8.796% (84/955) |
2 entries |
ENSG00000167548 |
|
mucosal melanoma |
missense_variant |
4.286% (3/70) |
1 entry |
ENSG00000167548 |
|
breast ductal adenocarcinoma |
sequence_alteration |
3.14% (54/1720) |
1 entry |
ENSG00000167548 |
|
gastric adenocarcinoma |
stop_gained |
7.592% (58/764) |
2 entries |
ENSG00000167548 |
|
Mantle cell lymphoma |
conservative_inframe_deletion |
20.39% (21/103) |
1 entry |
ENSG00000167548 |
|
ulcerative colitis |
missense_variant |
44.44% (4/9) |
1 entry |
ENSG00000167548 |
|
Breast Carcinoma by Gene Expression Profile |
frameshift_variant |
7.955% (105/1320) |
2 entries |
ENSG00000167548 |
|
clear cell renal carcinoma |
missense_variant |
1.743% (32/1836) |
7 entries |
ENSG00000167548 |
|
myelodysplastic syndrome |
amino_acid_insertion |
4.179% (29/694) |
1 entry |
ENSG00000167548 |
|
small intestinal adenocarcinoma |
missense_variant |
14.29% (3/21) |
1 entry |
ENSG00000167548 |
|
gastric adenocarcinoma |
sequence_alteration |
7.592% (58/764) |
1 entry |
ENSG00000167548 |
|
Breast Diffuse Large B-Cell Lymphoma |
missense_variant |
10.53% (2/19) |
1 entry |
ENSG00000167548 |
|
breast carcinoma |
missense_variant |
2.75% (47/1709) |
5 entries |
ENSG00000167548 |
|
cervical squamous cell carcinoma |
stop_gained |
5.538% (18/325) |
1 entry |
ENSG00000167548 |
|
HER2 Positive Breast Carcinoma |
missense_variant |
7.018% (8/114) |
1 entry |
ENSG00000167548 |
|
pancreatic ductal adenocarcinoma |
missense_variant |
3.432% (59/1719) |
3 entries |
ENSG00000167548 |
|
gastric intestinal type adenocarcinoma |
stop_gained |
12.04% (13/108) |
2 entries |
ENSG00000167548 |
|
rectal adenocarcinoma |
sequence_alteration |
4.762% (26/546) |
1 entry |
ENSG00000167548 |
|
thyroid carcinoma |
missense_variant |
2.7% (25/926) |
1 entry |
ENSG00000167548 |
|
prostate adenocarcinoma |
missense_variant |
3.935% (85/2160) |
4 entries |
ENSG00000167548 |
|
neuroendocrine carcinoma |
stop_gained |
42.86% (3/7) |
1 entry |
ENSG00000167548 |
|
chronic lymphocytic leukemia |
missense_variant |
0.9858% (9/913) |
1 entry |
ENSG00000167548 |
|
lobular breast carcinoma |
missense_variant |
3.261% (9/276) |
1 entry |
ENSG00000167548 |
|
acute myeloid leukemia |
stop_gained |
1.063% (28/2633) |
2 entries |
ENSG00000167548 |
|
diffuse large B-cell lymphoma |
conservative_inframe_deletion |
27.71% (143/516) |
1 entry |
ENSG00000167548 |
|
head and neck squamous cell carcinoma |
stop_gained |
4.147% (27/651) |
1 entry |
ENSG00000167548 |
|
papillary renal cell carcinoma |
missense_variant |
2.785% (11/395) |
3 entries |
ENSG00000167548 |
|
head and neck squamous cell carcinoma |
missense_variant |
4.147% (27/651) |
2 entries |
ENSG00000167548 |
|
anaplastic oligodendroglioma |
missense_variant |
9.302% (8/86) |
1 entry |
ENSG00000167548 |
|
clear cell renal carcinoma |
stop_gained |
1.743% (32/1836) |
1 entry |
ENSG00000167548 |
|
desmoplastic medulloblastoma |
sequence_alteration |
14.71% (5/34) |
1 entry |
ENSG00000167548 |
|
chronic myelomonocytic leukemia |
missense_variant |
7.143% (11/154) |
2 entries |
ENSG00000167548 |
|
breast carcinoma |
frameshift_variant |
2.75% (47/1709) |
2 entries |
ENSG00000167548 |
|
Breast Carcinoma by Gene Expression Profile |
amino_acid_insertion |
7.955% (105/1320) |
1 entry |
ENSG00000167548 |
|
lung adenocarcinoma |
missense_variant |
5.621% (147/2615) |
9 entries |
ENSG00000167548 |
|
large cell medulloblastoma |
frameshift_variant |
15.0% (6/40) |
3 entries |
ENSG00000167548 |
|
Fibroadenoma |
missense_variant |
6.757% (5/74) |
1 entry |
ENSG00000167548 |
|
pancreatic ductal adenocarcinoma |
frameshift_variant |
3.432% (59/1719) |
3 entries |
ENSG00000167548 |
|
basal cell carcinoma |
frameshift_variant |
35.29% (24/68) |
1 entry |
ENSG00000167548 |
|
Dysplasia in Ulcerative Colitis |
missense_variant |
37.5% (3/8) |
1 entry |
ENSG00000167548 |
|
Gallbladder Adenocarcinoma |
missense_variant |
4.651% (8/172) |
3 entries |
ENSG00000167548 |
|
squamous cell lung carcinoma |
missense_variant |
8.796% (84/955) |
4 entries |
ENSG00000167548 |
|
adrenal gland pheochromocytoma |
missense_variant |
3.191% (9/282) |
1 entry |
ENSG00000167548 |
|
pharyngeal squamous cell carcinoma |
missense_variant |
11.11% (9/81) |
1 entry |
ENSG00000167548 |
|
Breast Carcinoma by Gene Expression Profile |
stop_gained |
7.955% (105/1320) |
2 entries |
ENSG00000167548 |
|
brain glioblastoma |
sequence_alteration |
1.731% (21/1213) |
2 entries |
ENSG00000167548 |
|
esophageal adenocarcinoma |
missense_variant |
3.285% (18/548) |
2 entries |
ENSG00000167548 |
|
medulloblastoma |
frameshift_variant |
11.54% (3/26) |
1 entry |
ENSG00000167548 |
|
ovarian serous adenocarcinoma |
stop_gained |
1.779% (15/843) |
2 entries |
ENSG00000167548 |
|
Ovarian Granulosa Cell Tumor |
frameshift_variant |
13.33% (2/15) |
1 entry |
ENSG00000167548 |
|
skin carcinoma |
stop_gained |
2.885% (3/104) |
1 entry |
ENSG00000167548 |
|
gastric tubular adenocarcinoma |
frameshift_variant |
50.0% (1/2) |
1 entry |
ENSG00000167548 |
|
laryngeal squamous cell carcinoma |
missense_variant |
17.07% (7/41) |
1 entry |
ENSG00000167548 |
|
angioimmunoblastic T-cell lymphoma |
conservative_inframe_deletion |
4.348% (1/23) |
1 entry |
ENSG00000167548 |
|
follicular thyroid carcinoma |
frameshift_variant |
1.429% (1/70) |
1 entry |
ENSG00000167548 |
|
chromophobe renal cell carcinoma |
frameshift_variant |
2.454% (4/163) |
1 entry |
ENSG00000167548 |
|
salivary gland carcinoma |
stop_gained |
6.061% (2/33) |
1 entry |
ENSG00000167548 |
|
acute myeloid leukemia |
sequence_alteration |
1.063% (28/2633) |
1 entry |
ENSG00000167548 |
|
gastric tubular adenocarcinoma |
conservative_inframe_deletion |
50.0% (1/2) |
1 entry |
ENSG00000167548 |
|
Vaginal Squamous Cell Carcinoma |
frameshift_variant |
50.0% (1/2) |
1 entry |
ENSG00000167548 |
|
cervical carcinoma |
stop_gained |
8.696% (2/23) |
1 entry |
ENSG00000167548 |
|
medullary thyroid gland carcinoma |
frameshift_variant |
2.778% (1/36) |
1 entry |
ENSG00000167548 |
|
large cell lung carcinoma |
missense_variant |
5.263% (1/19) |
1 entry |
ENSG00000167548 |
|
Chordoma |
missense_variant |
7.143% (1/14) |
1 entry |
ENSG00000167548 |
|
Splenic Diffuse Large B-Cell Lymphoma |
stop_gained |
75.0% (3/4) |
1 entry |
ENSG00000167548 |
|
endometrial carcinoma |
frameshift_variant |
3.448% (1/29) |
1 entry |
ENSG00000167548 |
|
Ovarian Small Cell Carcinoma |
sequence_alteration |
6.667% (1/15) |
1 entry |
ENSG00000167548 |
|
astrocytoma |
missense_variant |
16.67% (1/6) |
1 entry |
ENSG00000167548 |
|
primary peritoneal carcinoma (disease) |
missense_variant |
100.0% (1/1) |
1 entry |
ENSG00000167548 |
|
Gastrointestinal stromal tumor |
stop_gained |
3.289% (5/152) |
1 entry |
ENSG00000167548 |
|
Duodenal Adenocarcinoma |
frameshift_variant |
11.76% (2/17) |
1 entry |
ENSG00000167548 |
|
chromophobe renal cell carcinoma |
stop_gained |
2.454% (4/163) |
1 entry |
ENSG00000167548 |
|
B-cell acute lymphoblastic leukemia |
amino_acid_insertion |
4.487% (7/156) |
1 entry |
ENSG00000167548 |
|
myelodysplastic syndrome |
conservative_inframe_deletion |
4.179% (29/694) |
1 entry |
ENSG00000167548 |
|
colonic neoplasm |
missense_variant |
6.667% (1/15) |
1 entry |
ENSG00000167548 |
|
hairy cell leukemia |
missense_variant |
4.167% (1/24) |
1 entry |
ENSG00000167548 |
|
Endometrial Undifferentiated Carcinoma |
missense_variant |
33.33% (1/3) |
1 entry |
ENSG00000167548 |
|
salivary gland squamous cell carcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000167548 |
|
large cell medulloblastoma |
missense_variant |
15.0% (6/40) |
1 entry |
ENSG00000167548 |
|
Cortisol-Producing Adrenal Cortex Adenoma |
frameshift_variant |
0.8065% (1/124) |
1 entry |
ENSG00000167548 |
|
gastric adenocarcinoma |
conservative_inframe_deletion |
7.592% (58/764) |
1 entry |
ENSG00000167548 |
|
dedifferentiated liposarcoma |
missense_variant |
2.222% (1/45) |
1 entry |
ENSG00000167548 |
|
B-cell acute lymphoblastic leukemia |
stop_gained |
4.487% (7/156) |
1 entry |
ENSG00000167548 |
|
clear cell renal carcinoma |
sequence_alteration |
1.743% (32/1836) |
1 entry |
ENSG00000167548 |
|
gastric intestinal type adenocarcinoma |
conservative_inframe_deletion |
12.04% (13/108) |
1 entry |
ENSG00000167548 |
|
medulloblastoma |
stop_gained |
11.54% (3/26) |
1 entry |
ENSG00000167548 |
|
osteosarcoma |
frameshift_variant |
0.6579% (1/152) |
1 entry |
ENSG00000167548 |
|
neuroendocrine carcinoma |
missense_variant |
42.86% (3/7) |
1 entry |
ENSG00000167548 |
|
Malignant Ovarian Mixed Epithelial Tumor |
missense_variant |
16.67% (1/6) |
1 entry |
ENSG00000167548 |
|
Thymic Undifferentiated Carcinoma |
frameshift_variant |
14.29% (1/7) |
1 entry |
ENSG00000167548 |
|
T-cell acute lymphoblastic leukemia |
sequence_alteration |
2.068% (14/677) |
1 entry |
ENSG00000167548 |
|
Ovarian Carcinosarcoma |
frameshift_variant |
7.143% (1/14) |
1 entry |
ENSG00000167548 |
|
laryngeal squamous cell carcinoma |
frameshift_variant |
17.07% (7/41) |
1 entry |
ENSG00000167548 |
|
colorectal adenoma |
missense_variant |
11.11% (1/9) |
1 entry |
ENSG00000167548 |
|
Thymic Carcinoma |
missense_variant |
27.27% (3/11) |
1 entry |
ENSG00000167548 |
|
Breast Diffuse Large B-Cell Lymphoma |
sequence_alteration |
10.53% (2/19) |
1 entry |
ENSG00000167548 |
|
chronic myelomonocytic leukemia |
conservative_inframe_deletion |
7.143% (11/154) |
1 entry |
ENSG00000167548 |
|
chronic myelomonocytic leukemia |
stop_gained |
7.143% (11/154) |
1 entry |
ENSG00000167548 |
|
embryonal rhabdomyosarcoma |
frameshift_variant |
3.488% (3/86) |
1 entry |
ENSG00000167548 |
|
Ampulla of Vater Carcinoma |
sequence_alteration |
4.706% (4/85) |
1 entry |
ENSG00000167548 |
|
follicular thyroid carcinoma |
missense_variant |
1.429% (1/70) |
1 entry |
ENSG00000167548 |
|
Thymic Carcinoma |
stop_gained |
27.27% (3/11) |
1 entry |
ENSG00000167548 |
|
esophageal adenocarcinoma |
stop_gained |
3.285% (18/548) |
1 entry |
ENSG00000167548 |
|
diffuse gastric adenocarcinoma |
sequence_alteration |
3.571% (4/112) |
1 entry |
ENSG00000167548 |
|
carcinosarcoma |
sequence_alteration |
100.0% (3/3) |
1 entry |
ENSG00000167548 |
|
Thymic Carcinoma |
frameshift_variant |
27.27% (3/11) |
1 entry |
ENSG00000167548 |
|
pharyngeal squamous cell carcinoma |
frameshift_variant |
11.11% (9/81) |
1 entry |
ENSG00000167548 |
|
solitary fibrous tumor |
stop_gained |
3.448% (1/29) |
1 entry |
ENSG00000167548 |
|
small intestinal adenocarcinoma |
frameshift_variant |
14.29% (3/21) |
1 entry |
ENSG00000167548 |
|
undifferentiated pleomorphic sarcoma |
frameshift_variant |
4.839% (3/62) |
1 entry |
ENSG00000167548 |
|
pancreatic neuroendocrine tumor |
stop_gained |
1.695% (4/236) |
1 entry |
ENSG00000167548 |
|
Appendix Adenocarcinoma |
sequence_alteration |
3.896% (3/77) |
1 entry |
ENSG00000167548 |
|
medulloblastoma |
sequence_alteration |
11.54% (3/26) |
1 entry |
ENSG00000167548 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
frameshift_variant |
3.788% (10/264) |
1 entry |
ENSG00000167548 |
|
gastric tubular adenocarcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000167548 |
|
Tonsillar Squamous Cell Carcinoma |
missense_variant |
11.11% (1/9) |
1 entry |
ENSG00000167548 |
|
Vulvar Squamous Cell Carcinoma |
stop_gained |
5.263% (1/19) |
1 entry |
ENSG00000167548 |
|
Ampulla of Vater Carcinoma |
frameshift_variant |
4.706% (4/85) |
1 entry |
ENSG00000167548 |
|
Colorectal Neuroendocrine Tumor G1 |
missense_variant |
20.0% (1/5) |
1 entry |
ENSG00000167548 |
|
well-differentiated liposarcoma |
stop_gained |
5.556% (1/18) |
1 entry |
ENSG00000167548 |
|
salivary gland carcinoma |
frameshift_variant |
6.061% (2/33) |
1 entry |
ENSG00000167548 |
|
Ampulla of Vater Carcinoma |
stop_gained |
4.706% (4/85) |
1 entry |
ENSG00000167548 |
|
Cervical Adenosquamous Carcinoma |
frameshift_variant |
20.0% (1/5) |
1 entry |
ENSG00000167548 |
|
chronic myelomonocytic leukemia |
amino_acid_insertion |
7.143% (11/154) |
1 entry |
ENSG00000167548 |
|
Malignant Germ Cell Tumor |
missense_variant |
100.0% (1/1) |
1 entry |
ENSG00000167548 |
|
endometrium adenocarcinoma |
frameshift_variant |
6.667% (2/30) |
1 entry |
ENSG00000167548 |
|
Endometrial Clear Cell Adenocarcinoma |
missense_variant |
7.407% (2/27) |
1 entry |
ENSG00000167548 |
|
testicular seminoma |
frameshift_variant |
5.128% (4/78) |
1 entry |
ENSG00000167548 |
|
in situ carcinoma |
missense_variant |
100.0% (1/1) |
1 entry |
ENSG00000167548 |
|
Duodenal Adenocarcinoma |
missense_variant |
11.76% (2/17) |
1 entry |
ENSG00000167548 |
|
Invasive Breast Carcinoma |
frameshift_variant |
6.522% (3/46) |
1 entry |
ENSG00000167548 |
|
Appendix Adenocarcinoma |
missense_variant |
3.896% (3/77) |
1 entry |
ENSG00000167548 |
|
papillary thyroid carcinoma |
stop_gained |
1.174% (6/511) |
1 entry |
ENSG00000167548 |
|
Cutaneous Follicular Lymphoma |
stop_gained |
100.0% (2/2) |
1 entry |
ENSG00000167548 |
|
leiomyosarcoma |
missense_variant |
1.98% (2/101) |
1 entry |
ENSG00000167548 |
|
embryonal rhabdomyosarcoma |
stop_gained |
3.488% (3/86) |
1 entry |
ENSG00000167548 |
|
Minor Salivary Gland Adenocarcinoma |
conservative_inframe_deletion |
50.0% (1/2) |
1 entry |
ENSG00000167548 |
|
angiosarcoma |
missense_variant |
7.018% (4/57) |
1 entry |
ENSG00000167548 |
|
Adrenal Gland Neuroblastoma |
missense_variant |
1.667% (1/60) |
1 entry |
ENSG00000167548 |
|
clear cell renal carcinoma |
conservative_inframe_deletion |
1.743% (32/1836) |
1 entry |
ENSG00000167548 |
|
Sarcomatoid Mesothelioma |
missense_variant |
100.0% (1/1) |
1 entry |
ENSG00000167548 |
|
Appendix Goblet Cell Carcinoid |
sequence_alteration |
4.762% (1/21) |
1 entry |
ENSG00000167548 |
|
brain astrocytoma |
frameshift_variant |
2.083% (1/48) |
1 entry |
ENSG00000167548 |
|
breast carcinoma |
sequence_alteration |
2.75% (47/1709) |
1 entry |
ENSG00000167548 |
|
Gastric Neuroendocrine Tumor G1 |
missense_variant |
11.11% (1/9) |
1 entry |
ENSG00000167548 |
|
nasal cavity and paranasal sinus carcinoma |
missense_variant |
4.348% (1/23) |
1 entry |
ENSG00000167548 |
|
Merkel cell skin cancer |
sequence_alteration |
15.79% (15/95) |
1 entry |
ENSG00000167548 |
|
Testicular Yolk Sac Tumor |
amino_acid_insertion |
14.29% (1/7) |
1 entry |
ENSG00000167548 |
|
Anal Squamous Cell Carcinoma |
conservative_inframe_deletion |
14.46% (12/83) |
1 entry |
ENSG00000167548 |
|
Cervical Clear Cell Adenocarcinoma |
amino_acid_insertion |
100.0% (1/1) |
1 entry |
ENSG00000167548 |
|
female breast carcinoma |
stop_gained |
4.11% (12/292) |
1 entry |
ENSG00000167548 |
|
Merkel cell skin cancer |
frameshift_variant |
15.79% (15/95) |
1 entry |
ENSG00000167548 |
|
acute lymphoblastic leukemia |
amino_acid_insertion |
5.607% (18/321) |
1 entry |
ENSG00000167548 |
|
B-cell acute lymphoblastic leukemia |
missense_variant |
4.487% (7/156) |
1 entry |
ENSG00000167548 |
|
Benign Adrenal Gland Pheochromocytoma |
missense_variant |
3.03% (1/33) |
1 entry |
ENSG00000167548 |
|
Mixed Lobular and Ductal Breast Carcinoma |
stop_gained |
6.667% (5/75) |
1 entry |
ENSG00000167548 |
|
large cell medulloblastoma |
sequence_alteration |
15.0% (6/40) |
1 entry |
ENSG00000167548 |
|
alveolar soft part sarcoma |
missense_variant |
16.67% (1/6) |
1 entry |
ENSG00000167548 |
|
adrenocortical adenoma |
missense_variant |
2.439% (1/41) |
1 entry |
ENSG00000167548 |
|
Gallbladder Adenocarcinoma |
stop_gained |
4.651% (8/172) |
1 entry |
ENSG00000167548 |
|
Liver Cavernous Hemangioma |
missense_variant |
16.67% (1/6) |
1 entry |
ENSG00000167548 |
|
nasopharyngeal squamous cell carcinoma |
sequence_alteration |
8.696% (16/184) |
1 entry |
ENSG00000167548 |
|
ovarian adenocarcinoma |
missense_variant |
10.0% (1/10) |
1 entry |
ENSG00000167548 |
|
leiomyosarcoma |
frameshift_variant |
1.98% (2/101) |
1 entry |
ENSG00000167548 |
|
undifferentiated pleomorphic sarcoma |
stop_gained |
4.839% (3/62) |
1 entry |
ENSG00000167548 |
|
rectal adenocarcinoma |
stop_gained |
4.762% (26/546) |
1 entry |
ENSG00000167548 |
|
Pancreatic Acinar Cell Carcinoma |
missense_variant |
8.824% (3/34) |
1 entry |
ENSG00000167548 |
|
Mixed Lobular and Ductal Breast Carcinoma |
frameshift_variant |
6.667% (5/75) |
1 entry |
ENSG00000167548 |
|
ovarian serous adenocarcinoma |
frameshift_variant |
1.779% (15/843) |
1 entry |
ENSG00000167548 |
|
nasal cavity and paranasal sinus carcinoma |
stop_gained |
4.348% (1/23) |
1 entry |
ENSG00000167548 |
|
kidney Wilms tumor |
missense_variant |
0.3115% (1/321) |
1 entry |
ENSG00000167548 |
|
B-cell acute lymphoblastic leukemia |
sequence_alteration |
4.487% (7/156) |
1 entry |
ENSG00000167548 |
|
primary peritoneal carcinoma (disease) |
frameshift_variant |
100.0% (1/1) |
1 entry |
ENSG00000167548 |
|
dedifferentiated chondrosarcoma |
missense_variant |
5.882% (1/17) |
1 entry |
ENSG00000167548 |
|
Skin Basosquamous Cell Carcinoma |
stop_gained |
100.0% (1/1) |
1 entry |
ENSG00000167548 |
|
carcinoid tumor |
frameshift_variant |
16.67% (1/6) |
1 entry |
ENSG00000167548 |
|
ovarian serous adenocarcinoma |
conservative_inframe_deletion |
1.779% (15/843) |
1 entry |
ENSG00000167548 |
|
diffuse gastric adenocarcinoma |
missense_variant |
3.571% (4/112) |
1 entry |
ENSG00000167548 |
|
Thymic Squamous Cell Carcinoma |
missense_variant |
3.704% (1/27) |
1 entry |
ENSG00000167548 |
|
Pleural Epithelioid Mesothelioma |
sequence_alteration |
2.439% (5/205) |
1 entry |
ENSG00000167548 |
|
meningioma (disease) |
missense_variant |
1.37% (1/73) |
1 entry |
ENSG00000167548 |
|
Endometrial Clear Cell Adenocarcinoma |
stop_gained |
7.407% (2/27) |
1 entry |
ENSG00000167548 |
|
non-small cell lung carcinoma |
frameshift_variant |
5.155% (5/97) |
1 entry |
ENSG00000167548 |
|
multiple myeloma |
missense_variant |
2.222% (1/45) |
1 entry |
ENSG00000167548 |
|
Merkel cell skin cancer |
amino_acid_insertion |
15.79% (15/95) |
1 entry |
ENSG00000167548 |
|
rectal adenocarcinoma |
conservative_inframe_deletion |
4.762% (26/546) |
1 entry |
ENSG00000167548 |
|
acute myeloid leukemia |
amino_acid_insertion |
1.063% (28/2633) |
1 entry |
ENSG00000167548 |
|
esophageal adenocarcinoma |
conservative_inframe_deletion |
3.285% (18/548) |
1 entry |
ENSG00000167548 |
|
alveolar rhabdomyosarcoma |
stop_gained |
1.538% (1/65) |
1 entry |
ENSG00000167548 |
|
skin melanoma |
frameshift_variant |
8.755% (102/1165) |
1 entry |
ENSG00000167548 |
|
Parotid Gland Adenoid Cystic Carcinoma |
frameshift_variant |
7.692% (1/13) |
1 entry |
ENSG00000167548 |
|
Thymic Undifferentiated Carcinoma |
missense_variant |
14.29% (1/7) |
1 entry |
ENSG00000167548 |
|
renal cell carcinoma |
missense_variant |
1.449% (1/69) |
1 entry |
ENSG00000167548 |
|
Extraskeletal Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor |
stop_gained |
3.03% (1/33) |
1 entry |
ENSG00000167548 |
|
adrenal cortex carcinoma |
stop_gained |
1.587% (3/189) |
1 entry |
ENSG00000167548 |
|
Myelodysplastic/Myeloproliferative Neoplasm |
missense_variant |
7.143% (1/14) |
1 entry |
ENSG00000167548 |
|
Appendix Adenocarcinoma |
frameshift_variant |
3.896% (3/77) |
1 entry |
ENSG00000167548 |
|
endometrium adenocarcinoma |
stop_gained |
6.667% (2/30) |
1 entry |
ENSG00000167548 |
|
pseudomyxoma peritonei |
missense_variant |
10.0% (1/10) |
1 entry |
ENSG00000167548 |
|
Anal Squamous Cell Carcinoma |
sequence_alteration |
14.46% (12/83) |
1 entry |
ENSG00000167548 |
|
Breast Carcinoma by Gene Expression Profile |
sequence_alteration |
7.955% (105/1320) |
1 entry |
ENSG00000167548 |
|
Gastrointestinal stromal tumor |
sequence_alteration |
3.289% (5/152) |
1 entry |